Log on / register
Feedback | Support | My details

Pre-publication history

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

Kim A Papp email, Darryl Toth email and Les Rosoph email

BMC Dermatology 2006, 6:9doi:10.1186/1471-5945-6-9

Pre-publication versions of this article and reviewers' reports

Original submission - Version 1Manuscript11 May 2006
Reviewer's ReportDan Pearce23 Jun 2006
Reviewer's ReportJennifer Cather08 Jul 2006
Resubmission - Version 3ManuscriptAuthors' comments25 Aug 2006
Reviewer's ReportJennifer Cather13 Sep 2006
Reviewer's ReportDan Pearce02 Oct 2006
Resubmission - Version 4Manuscript20 Oct 2006
Resubmission - Version 5Manuscript23 Oct 2006
Accepted26 Oct 2006
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2008 BioMed Central Ltd unless otherwise stated